topic

345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)
Evan Yu, Se Hoon Park, Yi-Hsiu Huang, Mostefa Bennamoun, Lu Xu, Jeri Kim, Emmanuel Antonarakis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A210-A211; DOI: 10.1136/jitc-2020-SITC2020.0345
344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
Julie Nicole Graff, Joseph Burgents, Li Wen Liang, Arnulf Stenzl

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A210; DOI: 10.1136/jitc-2020-SITC2020.0344
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Christian Gratzke, Christian Gratzke, Christian Gratzke, Cuizhen Niu, Christian Poehlein, Joseph Burgents

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A211; DOI: 10.1136/jitc-2020-SITC2020.0346
356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab
Neil Berinstein, Isabelle Bence-Bruckler, Nick Forward, Pierre Laneuville, Joy Mangel, Douglas Stewart, Irina Amitai, Gail Klein, Nancy Pennell, Iran Rashedi, Kim Roos, Yogesh Bramhecha, Rebekah Conlon

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A217-A218; DOI: 10.1136/jitc-2020-SITC2020.0356
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma
Sabrina Collins, Adarsh Joshi, Lei Shen, Subhasree Das, Kaveri Suryanarayan, Dean Bottino, Cheryl Li, Michael Curley, Dannie Wang, Michael Abadier, Ryan Larson, Xavier Parot

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A218; DOI: 10.1136/jitc-2020-SITC2020.0357
358 Trial in progress: A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC)
Hailey Carroll, Umair Aleem, Pooja Varghese, Marie Galligan, Michèle Bourke, Katherine Hoey, Ronan Ryan, Peter Doran, Stephen Stewart, Cliona O’Farrelly, Tim Greten, Diarmaid Houlihan, Raymond McDermott, Austin Duffy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A218-A219; DOI: 10.1136/jitc-2020-SITC2020.0358
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
Hossein Borghaei, Michael Boyer, Melissa Johnson, Ramaswamy Govindan, Luis Paz-Ares Rodrigues, Fiona Blackhall, Rene Boosman, Stéphane Champiat, Horst-Dieter Hummel, W Victoria Lai, Hibiki Udagawa, Anne Chiang, Afshin Dowlati, Christine Hann, Ravi Salgia, Everett Vokes, Mukul Minocha, Nooshin Hashemi-Sadraei, Aditya Shetty, Marie-Anne Damiette Smit, Hui Yang, Taofeek Owonikoko

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A219-A220; DOI: 10.1136/jitc-2020-SITC2020.0359
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
Magnus Jaderberg, Susana Cedres, Luis Paz-Ares, Xavier Serres, Charles Ricordel, Nicolas Isambert, Santiago Ponce Aix, Victor Levitsky, Lukasz Kuryk, Anne-Sophie Moller, Sylvia Vetrhus

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A220-A221; DOI: 10.1136/jitc-2020-SITC2020.0361
368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
Adi Diab, Brendan Curti, Mehmet Bilen, Andrew Brohl, Evidio Domingo-Musibay, Erkut Borazanci, Christie Fanton, Cat Haglund, Mona Vimal, Mann Muhsin, Mario Marcondes, Anh Nguyen, Mary Tagliaferri, Wei Lin, Jonathan Zalevsky, Sandra D’Angelo

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A224-A225; DOI: 10.1136/jitc-2020-SITC2020.0368
370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors
Victor Moreno, Tatiana Hernandez, Ignacio Melero, Miguel Sanmamed, Iben Spanggaard, Kristoffer Staal Rohrberg, Josep Tabernero, Analia Azaro, Maria Martinez Garcia, Alejo Rodriguez-Vida, Christina Claus, Florian Heil, Oliver Krieter, Oliver Grimm, Marta Canamero, Jose Duarte, Alexandra-Cristina Nica, Iakov Davydov, Michael Hettich, Chia-Huey Ooi, Christian Heichinger, Ernesto Guarin, Radoiane Helbaj, Tamara Tanos, Eveline Nueesch, Maurizio Ceppi, Irene Moreno, Emiliano Calvo

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A225-A226; DOI: 10.1136/jitc-2020-SITC2020.0370

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages